Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
859 participants
INTERVENTIONAL
2009-06-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Degarelix Trial in Patients With Prostate Cancer
NCT01242748
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
NCT00801242
A Study of Degarelix in Patients With Prostate Cancer
NCT00928434
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
NCT00468286
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
NCT00116753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Degarelix 240 mg/480 mg
Degarelix
The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
Goserelin acetate
Goserelin acetate
The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Degarelix
The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
Goserelin acetate
The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a histological confirmed prostate cancer Gleason graded).
* Has a screening testosterone above 2.2 ng/mL.
* Rising prostate-specific antigen (PSA).
* Has Eastern Cooperative Oncology Group (ECOG) score of ≤ 2.
* Has a life expectancy of at least one year.
Exclusion Criteria
* Has received therapy with finasteride and dutasteride within 12 weeks and 25 weeks, respectively, prior to screening.
* Has a history of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
* Has a heart insufficiency.
* Has a previous history or presence of another malignancy, other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last five years.
* Has a clinically significant medical condition (other than prostate cancer) including, but not limited to, renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease and alcohol or drug abuse or any other condition which may affect the patient's health or the outcome of the trial as judged by the Investigator.
* Has received an investigational drug within the last 28 days before the Screening Visit or longer if considered to possibly influencing the outcome of the current trial.
* Is candidate for curative therapy, i.e. radical prostatectomy or radiotherapy.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferring Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Development Support
Role: STUDY_DIRECTOR
Ferring Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urology Centers Of Alabama
Homewood, Alabama, United States
Arkansas Urology
Little Rock, Arkansas, United States
Urology Associates of Central CA
Fresno, California, United States
Medresearch
La Mesa, California, United States
South Orange County Medical Research Center
Laguna Hills, California, United States
Atlantic Urology Medical Group
Long Beach, California, United States
Anschutz Cancer Pavillion
Aurora, Colorado, United States
The Urology Center of Colorado
Denver, Colorado, United States
Urological Associates of Bridgeport, P.C.
Trumbull, Connecticut, United States
Urology Associates of Dover, PA
Dover, Delaware, United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, United States
South Florida Medical Research
Aventura, Florida, United States
Florida Foundation for Healthcare Research
Ocala, Florida, United States
Georgis Patsias, MD, PA
Wellington, Florida, United States
Palm Beach Urology Associates, PA
Wellington, Florida, United States
Indiana University Department of Urology
Indianapolis, Indiana, United States
Kansas City Urology Care, PA
Overland Park, Kansas, United States
Urological Associates of Englewood
Englewood, New Jersey, United States
Hamilton Urology PA
Hamilton, New Jersey, United States
Lawrenceville Urology
Lawrenceville, New Jersey, United States
Urology Group of New Mexico, PC
Albuquerque, New Mexico, United States
Capital Region Urological Surgeons and Research Associates
Albany, New York, United States
Hudson Valley Urology P.C.
Poughkeepsie, New York, United States
Metrolina Urology Clinic
Charlotte, North Carolina, United States
Northeast Urology Research
Concord, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Alliance Urology Specialists
Greensboro, North Carolina, United States
Urologic Consultants of SEPA
Bala-Cynwyd, Pennsylvania, United States
State College Urologic Association
State College, Pennsylvania, United States
Grand Strand Urology
Myrtle Beach, South Carolina, United States
Urology Clinics of North Texas, PA
Dallas, Texas, United States
Urology San Antonio Research
San Antonio, Texas, United States
Urology of Virginia
Norfolk, Virginia, United States
Virginia Urology Center
Richmond, Virginia, United States
Urology of Virginia
Virginia Beach, Virginia, United States
Seattle Urology Research Center
Burien, Washington, United States
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
UZ Antwerpen
Edegem, , Belgium
UZ Gent
Ghent, , Belgium
AZ Groeninge - Campus Sint-Maarten
Kortrijk, , Belgium
Southern Interior Medical Research Inc.
Kelowna, British Columbia, Canada
Dr. Cal Andreou Research
Surrey, British Columbia, Canada
Can-Med Clinical Research Inc.
Victoria, British Columbia, Canada
Dr Gary Steinhoff Clinical Research
Victoria, British Columbia, Canada
Bramalea Medical Centre
Brampton, Ontario, Canada
Urology Associates / Urologic Medical Research
Kitchener, Ontario, Canada
Mor Urology, Inc.
Newmarket, Ontario, Canada
Ivestigational site
Scarborough Village, Ontario, Canada
Anthony Skehan Medicine Professionals Corporation
Thunder Bay, Ontario, Canada
Bloor West Professional Center
Toronto, Ontario, Canada
The Health Institute for Men
Toronto, Ontario, Canada
Uro Laval
Laval, Quebec, Canada
Notre Dame Hopital
Montreal, , Canada
Urocentrum Brno
Brno, , Czechia
Nemocnice Jindrichuv Hradec, a.s.
Jindřichův Hradec, , Czechia
Kromerizska nemocnice a.s.
Kroměříž, , Czechia
Slezska nemocnice
Opava, , Czechia
Fakultni nemocnice v Motole, Praha 5
Prague, , Czechia
Fakultni Thomayerova nemocnice s poliklinikou, Praha 4
Prague, , Czechia
Vseobecna fakultni nemocnice v Praze, Praha 2
Prague, , Czechia
Krajska nemocnice T. Bati a.s.
Zlín, , Czechia
Pietarsaaren sairaala/ Malmin terveydenhuoltoalue
Jakobstad, , Finland
Pohjois-Karjalan keskussairaala
Joensuu, , Finland
ODL Terveys Oy
Oulu, , Finland
Tampereen yliopistollinen sairaala
Tampere, , Finland
Investigational site
Aachen, , Germany
Investigational site
Kirchheim, , Germany
Klinikum Mannheim Universitätsklinikum GmbH
Mannheim, , Germany
Urologische Studienpraxis
Nürtingen, , Germany
Fövárosi Önkormányzat Bajcsy-Zsilinszky Kórház
Budapest, , Hungary
Fövárosi Önkormányzat uzsoki utcai Kórház
Budapest, , Hungary
Semmelweis Egyetem
Budapest, , Hungary
Dombóvári Szent Lukács Egészségügyi Kht.
Dombóvár, , Hungary
Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház
Miskolc, , Hungary
Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház Nonprofit Kft
Miskolc, , Hungary
Pécsi Tudományegyetem
Pécs, , Hungary
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, , Hungary
Jávorszky Ödön Kórház
Vác, , Hungary
Hospital Christus Muguerza del Parque
Chihuahua City, Chihuahua, Mexico
Hospital Aranda de la Parra , S.A. de C.V.
León, Guanajuato, Mexico
Hospital Angeles Culiacan
Culiacán, Sinaloa, Mexico
Consultorio de Especialidad en Urologia Privado, Durango
Durango, , Mexico
Centro Medico Dalinde
Mexico City, , Mexico
Hospital Angeles Lindavista
Mexico City, , Mexico
Operadora MSB, S.A. de C.V. (Medica Sur CIF-BIOTEC)
Mexico City, , Mexico
Consultorio Medico
Zapopan, Jalisco, , Mexico
AMC
Amsterdam, , Netherlands
Catharina-ziekenhuis
Eindhoven, , Netherlands
Atrium MC
Heerlen, , Netherlands
MC Haaglanden
The Hague, , Netherlands
SPZOZ Wojewodzki Szpital Zespolony im. J.Sniadeckiego
Bialystok, , Poland
Centrum Medyczne Medur Sp. z o.o.
Bielsko-Biala, , Poland
Gabinet Lekarski
Krakow, , Poland
Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku
Słupsk, , Poland
LexMedica
Wroclaw, , Poland
Private Medical Center
Arad, , Romania
Brasov Emergency Clinical County Hospital
Brasov, , Romania
"Fundeni" Clinical Institute
Bucharest, , Romania
"Sfantul Ioan" Emergency Clinical Hospital
Bucharest, , Romania
Dinu Uromedica
Bucharest, , Romania
Prof. Dr. Th. Burghele Clinical Urology Hospital
Bucharest, , Romania
PROVITA 2000 Medical Center
Constanța, , Romania
"Dr. C.I. Parhon" Clinical Hospital
Lasi, , Romania
Vita Care Flav Medical Center
Piteşti, , Romania
Emergency County Clinical Hospital Sibiu
Sibiu, , Romania
City Clinical Hospital #60
Moscow, , Russia
Moscow State University of Medicine and Dentistry
Moscow, , Russia
"Clinic Andros" LLC
Saint Petersburg, , Russia
"Orkli" LLC
Saint Petersburg, , Russia
City Hospital # 26
Saint Petersburg, , Russia
City Hospital #15
Saint Petersburg, , Russia
St. Petersburg State Medical University n.a. I.P. Pavlov
Saint Petersburg, , Russia
St.Petersburg Multi-Field City Hospital #2
Saint Petersburg, , Russia
Regional Clinical Oncology Center
Vladimir, , Russia
Municipal Institution "Cherkasy Regional Oncology Dispensary"
Cherkassy, , Ukraine
Dnipropetrovsk State Medical Academy
Dnipropetrovsk, , Ukraine
Donetsk Regional Clinical Territorial Medical Association
Donetsk, , Ukraine
Ivano-Frankivsk Regional Oncology Dispensary
Ivano-Frankivsk, , Ukraine
Regional Clinical Center of Urology and Nephrology n.a. V.I.Shapoval
Kharkiv, , Ukraine
Kyiv City Clinical Hospital #3
Kyiv, , Ukraine
Odesa Regional Clinical Hospital
Odesa, , Ukraine
Municipal Institution "Zaporizhzhia Regional Clinical Hospital"
Zaporizhzhya, , Ukraine
Castle Hill Hospital
Cottingham, , United Kingdom
Ipswich Hospital
Ipswich, , United Kingdom
Royal Liverpool University Hospital
Liverpool, , United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-005276-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
FE200486 CS35
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.